icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
Fu8Nc9FSTsfH3TT3